COVID-19暴露后预防:系统综述

Q3 Pharmacology, Toxicology and Pharmaceutics
SeyedAhmad SeyedAlinaghi, Amirali Karimi, Zahra Pashaei, Parnian Shobeiri, Nazanin Janfaza, Farzane Behnezhad, Afsaneh Ghasemzadeh, Alireza Barzegary, Ghazal Arjmand, Alireza Noroozi, Alireza Shojaei, Ava Amiri, Farzin Vahedi, Mehrdad Mahalleh, Ahmadreza Shamsabadi, Mohsen Dashti, Amir Masoud Afsahi, Esmaeil Mehraeen, Omid Dadras
{"title":"COVID-19暴露后预防:系统综述","authors":"SeyedAhmad SeyedAlinaghi,&nbsp;Amirali Karimi,&nbsp;Zahra Pashaei,&nbsp;Parnian Shobeiri,&nbsp;Nazanin Janfaza,&nbsp;Farzane Behnezhad,&nbsp;Afsaneh Ghasemzadeh,&nbsp;Alireza Barzegary,&nbsp;Ghazal Arjmand,&nbsp;Alireza Noroozi,&nbsp;Alireza Shojaei,&nbsp;Ava Amiri,&nbsp;Farzin Vahedi,&nbsp;Mehrdad Mahalleh,&nbsp;Ahmadreza Shamsabadi,&nbsp;Mohsen Dashti,&nbsp;Amir Masoud Afsahi,&nbsp;Esmaeil Mehraeen,&nbsp;Omid Dadras","doi":"10.2174/1871526523666230413082721","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>SARS-CoV-2 cause pneumonia can spread across the lung and lead to acute respiratory distress syndrome (ARDS) in severe cases. Post-exposure prophylaxis has shown great potential to prevent the transmission of some viral infections; however, such results for COVID-19 are still inconclusive.</p><p><strong>Methods: </strong>Therefore, the aim of this study was to systematically review the resources that utilized postexposure prophylaxis (PEP) for COVID-19 and the possible clinical benefits of such drugs. An organized search of relevant literature was done using the keywords and search queries on public databases of Cochrane, PubMed, Web of Science and Scopus from December 2019 to August 23, 2021. Original resources that had the inclusion criteria were included after two-phase title/abstract and full-text screenings. This review adhered to the Preferred Reporting Items for Systematic Reviews and Meta- Analysis (PRISMA) statement.</p><p><strong>Results: </strong>Out of 841 retrieved records 17 resources were appropriate to include in the systematic review. Hydroxychloroquine with a daily dose of 400-800 mg and a duration of 5-14 days was the most frequently used agent for PEP. Chloroquine was recommended to use to control treatment in patients with mild to severe COVID-19 pneumonia. Other agents like Lopinavir-ritonavir (LPV/r), angiotensinconverting enzyme inhibitors (ACEIs), Angiotensin receptor blockers (ARBs), Vitamin D, arbidol, thymosin drugs, and Xin guan no.1 (XG.1, a Chinese formula medicine) have also been applied in some studies.</p><p><strong>Conclusion: </strong>Current evidence demonstrated no established clinical benefits of any drug as PEP in individuals with COVID-19. However, scarce indication occurs for the beneficial effects of some agents, but more studies are needed to explore such effects.</p>","PeriodicalId":13678,"journal":{"name":"Infectious disorders drug targets","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Post-Exposure Prophylaxis for COVID-19: A Systematic Review.\",\"authors\":\"SeyedAhmad SeyedAlinaghi,&nbsp;Amirali Karimi,&nbsp;Zahra Pashaei,&nbsp;Parnian Shobeiri,&nbsp;Nazanin Janfaza,&nbsp;Farzane Behnezhad,&nbsp;Afsaneh Ghasemzadeh,&nbsp;Alireza Barzegary,&nbsp;Ghazal Arjmand,&nbsp;Alireza Noroozi,&nbsp;Alireza Shojaei,&nbsp;Ava Amiri,&nbsp;Farzin Vahedi,&nbsp;Mehrdad Mahalleh,&nbsp;Ahmadreza Shamsabadi,&nbsp;Mohsen Dashti,&nbsp;Amir Masoud Afsahi,&nbsp;Esmaeil Mehraeen,&nbsp;Omid Dadras\",\"doi\":\"10.2174/1871526523666230413082721\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>SARS-CoV-2 cause pneumonia can spread across the lung and lead to acute respiratory distress syndrome (ARDS) in severe cases. Post-exposure prophylaxis has shown great potential to prevent the transmission of some viral infections; however, such results for COVID-19 are still inconclusive.</p><p><strong>Methods: </strong>Therefore, the aim of this study was to systematically review the resources that utilized postexposure prophylaxis (PEP) for COVID-19 and the possible clinical benefits of such drugs. An organized search of relevant literature was done using the keywords and search queries on public databases of Cochrane, PubMed, Web of Science and Scopus from December 2019 to August 23, 2021. Original resources that had the inclusion criteria were included after two-phase title/abstract and full-text screenings. This review adhered to the Preferred Reporting Items for Systematic Reviews and Meta- Analysis (PRISMA) statement.</p><p><strong>Results: </strong>Out of 841 retrieved records 17 resources were appropriate to include in the systematic review. Hydroxychloroquine with a daily dose of 400-800 mg and a duration of 5-14 days was the most frequently used agent for PEP. Chloroquine was recommended to use to control treatment in patients with mild to severe COVID-19 pneumonia. Other agents like Lopinavir-ritonavir (LPV/r), angiotensinconverting enzyme inhibitors (ACEIs), Angiotensin receptor blockers (ARBs), Vitamin D, arbidol, thymosin drugs, and Xin guan no.1 (XG.1, a Chinese formula medicine) have also been applied in some studies.</p><p><strong>Conclusion: </strong>Current evidence demonstrated no established clinical benefits of any drug as PEP in individuals with COVID-19. However, scarce indication occurs for the beneficial effects of some agents, but more studies are needed to explore such effects.</p>\",\"PeriodicalId\":13678,\"journal\":{\"name\":\"Infectious disorders drug targets\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Infectious disorders drug targets\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/1871526523666230413082721\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious disorders drug targets","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1871526523666230413082721","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

摘要

简介:SARS-CoV-2引起的肺炎可通过肺部传播,严重者可导致急性呼吸窘迫综合征(ARDS)。暴露后预防已显示出防止某些病毒感染传播的巨大潜力;然而,对COVID-19的这种结果仍然没有定论。方法:因此,本研究的目的是系统地回顾使用暴露后预防(PEP)治疗COVID-19的资源及其可能的临床益处。利用Cochrane、PubMed、Web of Science、Scopus等公共数据库2019年12月至2021年8月23日的关键词和搜索查询,对相关文献进行组织检索。具有纳入标准的原始资源经过两阶段标题/摘要和全文筛选后纳入。本综述遵循系统评价和Meta分析的首选报告项目(PRISMA)声明。结果:在841份检索记录中,17份资源适合纳入系统评价。羟基氯喹是PEP最常用的药物,日剂量400 ~ 800 mg,持续时间5 ~ 14天。建议在轻至重度COVID-19肺炎患者中使用氯喹控制治疗。其他药物如洛匹那韦-利托那韦(LPV/r)、血管紧张素转换酶抑制剂(ACEIs)、血管紧张素受体阻滞剂(ARBs)、维生素D、阿比多尔、胸腺苷类药物、新冠1号等(XG.1,一种中药方剂)也被应用于一些研究中。结论:目前的证据表明,任何药物作为PEP对COVID-19患者没有确定的临床益处。然而,一些药物的有益作用缺乏指征,需要更多的研究来探索这些作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Post-Exposure Prophylaxis for COVID-19: A Systematic Review.

Introduction: SARS-CoV-2 cause pneumonia can spread across the lung and lead to acute respiratory distress syndrome (ARDS) in severe cases. Post-exposure prophylaxis has shown great potential to prevent the transmission of some viral infections; however, such results for COVID-19 are still inconclusive.

Methods: Therefore, the aim of this study was to systematically review the resources that utilized postexposure prophylaxis (PEP) for COVID-19 and the possible clinical benefits of such drugs. An organized search of relevant literature was done using the keywords and search queries on public databases of Cochrane, PubMed, Web of Science and Scopus from December 2019 to August 23, 2021. Original resources that had the inclusion criteria were included after two-phase title/abstract and full-text screenings. This review adhered to the Preferred Reporting Items for Systematic Reviews and Meta- Analysis (PRISMA) statement.

Results: Out of 841 retrieved records 17 resources were appropriate to include in the systematic review. Hydroxychloroquine with a daily dose of 400-800 mg and a duration of 5-14 days was the most frequently used agent for PEP. Chloroquine was recommended to use to control treatment in patients with mild to severe COVID-19 pneumonia. Other agents like Lopinavir-ritonavir (LPV/r), angiotensinconverting enzyme inhibitors (ACEIs), Angiotensin receptor blockers (ARBs), Vitamin D, arbidol, thymosin drugs, and Xin guan no.1 (XG.1, a Chinese formula medicine) have also been applied in some studies.

Conclusion: Current evidence demonstrated no established clinical benefits of any drug as PEP in individuals with COVID-19. However, scarce indication occurs for the beneficial effects of some agents, but more studies are needed to explore such effects.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Infectious disorders drug targets
Infectious disorders drug targets Pharmacology, Toxicology and Pharmaceutics-Pharmacology
CiteScore
3.10
自引率
0.00%
发文量
123
期刊介绍: Infectious Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in infectious disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in infectious disorders. As the discovery, identification, characterization and validation of novel human drug targets for anti-infective drug discovery continues to grow, this journal will be essential reading for all pharmaceutical scientists involved in drug discovery and development.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信